Starting on:
Sep 5, 2025
Ending on:
Nov 4, 2025
Moderator(s):
Boardroom
Max Credits:
3 Points
Provider:
Plainsview Nursing Home
Claim Points
Sep 5, 2025
Ending on:
Nov 4, 2025
Moderator(s):
Dr.
Evelyn Ndungu
MBChB
Venue: MBChB
Boardroom
Max Credits:
3 Points
Provider:
Plainsview Nursing Home
Claim Points
Malaria Treatment guidelines
Starting on:
Sep 5, 2025
Sep 5, 2025
Ending on:
Nov 4, 2025
Nov 4, 2025
Venue:
Boardroom
Boardroom
Description
Malaria treatment guidelines depend on the infecting Plasmodium species, the patient's clinical status, and drug susceptibility based on the geographic area. For uncomplicated P. falciparum malaria in chloroquine-resistant areas, artemisinin-based combination therapies (ACTs) like Artemether-lumefantrine are recommended, with doses adjusted for weight and administered over 3 days. P. vivax and P. ovale require additional treatment for hypnozoites with drugs like primaquine or tafenoquine, which necessitates G6PD testing due to a risk of hemolytic anemia. Severe malaria requires hospitalization and parenteral treatment, often with IV artesunate.
Objectives
Treatment by Plasmodium species and severity
Uncomplicated P. falciparum :
Chloroquine-resistant areas: The recommended treatment is an ACT, such as Artemether-lumefantrine, given over 3 days.
Chloroquine-sensitive areas: Chloroquine can be used.
Uncomplicated P. vivax and P. ovale :
Requires a blood-stage treatment and an additional drug to eradicate dormant liver forms (hypnozoites).
G6PD testing: is required before administering primaquine or tafenoquine to prevent a severe reaction called hemolytic anemia.
Presenters
-
Dr.
Evelyn Ndungu